Vanda Pharmaceuticals Launches NEREUS™: A Breakthrough for Motion Sickness After Four Decades
Vanda Pharmaceuticals Inc. has announced an exciting advancement in the realm of motion sickness treatment. Their newly launched medication, NEREUS™ (tradipitant), is now available for purchase across the United States, marking a significant milestone in pharmaceutical history as it is the first new prescription medication approved for this common ailment in over 40 years. This innovation not only brings hope to an estimated 65 to 78 million Americans who suffer from motion sickness, but it also introduces a revolutionary approach to treatment.
Historically, motion sickness has been a challenge faced by many, affecting approximately 25 to 30 percent of adults during various modes of transport such as cars, planes, and boats. The symptoms of this condition can greatly hinder travel experiences, leading to discomfort and distress. Until now, individuals affected by this condition had seen little in the way of new solutions. NEREUS™, however, offers a modern alternative by acting as a neurokinin-1 (NK-1) receptor antagonist, which targets the process that triggers nausea and vomiting in response to motion.
According to Dr. Mihael H. Polymeropoulos, the President, CEO, and Chairman of Vanda, the introduction of NEREUS™ represents not just a new product launch, but a beacon of relief for millions. "Today marks an important milestone for the tens of millions of Americans who experience motion sickness symptoms during common travel," he stated. The drug functions by blocking the vomiting center in the brain, providing a pinpoint solution to a pervasive issue that has long gone unaddressed.
With a simple dosing regimen—one or two capsules taken approximately one hour before travel—NEREUS™ presents a user-friendly option for travelers. Patients can conveniently access this medication through the newly unveiled direct-to-consumer platform at nereus.us, or through retail pharmacies. At a cash-pay price of $85 per dose, this offering presents a significant cost-saving over the standard list price of $255.
Historically significant, the issue of motion sickness has influenced everything from military effectiveness during wars to space exploration. For instance, during Napoleon's campaign in Egypt in 1798, soldiers in the camel corps suffered from severe nausea, impacting their readiness for battle. Similarly, on D-Day in 1944, Allied paratroopers experienced severe air sickness en route to Normandy. In the world of space travel, nearly 70 percent of astronauts have grappled with motion sickness, presenting challenges for major space missions since the 1960s.
The Food and Drug Administration (FDA) approved NEREUS™ on December 30, 2025, following comprehensive Phase 3 clinical trials: Motion Syros and Motion Serifos, which assessed the drug's efficacy in real-world conditions on the open sea. Both studies demonstrated that NEREUS™ significantly outperformed placebo in preventing vomiting, underscoring its effectiveness during actual travel scenarios.
This favorable update on the pharmaceutical front could significantly alter the travel experience for many. As people prepare to embark on journeys in various modes of transport, the availability of NEREUS™ is bound to provide much-needed relief from the debilitating effects of motion sickness. To access NEREUS™, patients can visit the dedicated platform at nereus.us, where they can find more information and place an order.
As a leading firm in biopharmaceuticals, Vanda Pharmaceuticals continues its commitment to addressing unmet medical needs with innovative solutions. More information about the company and its offerings can be found at www.vandapharma.com, and they encourage discussions about the medication with healthcare providers to ensure informed and effective use.
In conclusion, the arrival of NEREUS™ signifies more than just a new product; it embodies a pivotal shift in the treatment landscape of motion sickness. By addressing a long-standing issue with a contemporary solution, Vanda Pharmaceuticals is set to improve the quality of life for millions of Americans who have endured the unwelcome symptoms of motion sickness for far too long.
Historically, motion sickness has been a challenge faced by many, affecting approximately 25 to 30 percent of adults during various modes of transport such as cars, planes, and boats. The symptoms of this condition can greatly hinder travel experiences, leading to discomfort and distress. Until now, individuals affected by this condition had seen little in the way of new solutions. NEREUS™, however, offers a modern alternative by acting as a neurokinin-1 (NK-1) receptor antagonist, which targets the process that triggers nausea and vomiting in response to motion.
According to Dr. Mihael H. Polymeropoulos, the President, CEO, and Chairman of Vanda, the introduction of NEREUS™ represents not just a new product launch, but a beacon of relief for millions. "Today marks an important milestone for the tens of millions of Americans who experience motion sickness symptoms during common travel," he stated. The drug functions by blocking the vomiting center in the brain, providing a pinpoint solution to a pervasive issue that has long gone unaddressed.
With a simple dosing regimen—one or two capsules taken approximately one hour before travel—NEREUS™ presents a user-friendly option for travelers. Patients can conveniently access this medication through the newly unveiled direct-to-consumer platform at nereus.us, or through retail pharmacies. At a cash-pay price of $85 per dose, this offering presents a significant cost-saving over the standard list price of $255.
Historically significant, the issue of motion sickness has influenced everything from military effectiveness during wars to space exploration. For instance, during Napoleon's campaign in Egypt in 1798, soldiers in the camel corps suffered from severe nausea, impacting their readiness for battle. Similarly, on D-Day in 1944, Allied paratroopers experienced severe air sickness en route to Normandy. In the world of space travel, nearly 70 percent of astronauts have grappled with motion sickness, presenting challenges for major space missions since the 1960s.
The Food and Drug Administration (FDA) approved NEREUS™ on December 30, 2025, following comprehensive Phase 3 clinical trials: Motion Syros and Motion Serifos, which assessed the drug's efficacy in real-world conditions on the open sea. Both studies demonstrated that NEREUS™ significantly outperformed placebo in preventing vomiting, underscoring its effectiveness during actual travel scenarios.
This favorable update on the pharmaceutical front could significantly alter the travel experience for many. As people prepare to embark on journeys in various modes of transport, the availability of NEREUS™ is bound to provide much-needed relief from the debilitating effects of motion sickness. To access NEREUS™, patients can visit the dedicated platform at nereus.us, where they can find more information and place an order.
As a leading firm in biopharmaceuticals, Vanda Pharmaceuticals continues its commitment to addressing unmet medical needs with innovative solutions. More information about the company and its offerings can be found at www.vandapharma.com, and they encourage discussions about the medication with healthcare providers to ensure informed and effective use.
In conclusion, the arrival of NEREUS™ signifies more than just a new product; it embodies a pivotal shift in the treatment landscape of motion sickness. By addressing a long-standing issue with a contemporary solution, Vanda Pharmaceuticals is set to improve the quality of life for millions of Americans who have endured the unwelcome symptoms of motion sickness for far too long.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.